Deciphera Pharmaceuticals, Inc. (DCPH) financial statements (2020 and earlier)

Company profile

Business Address 200 SMITH STREET
WALTHAM, MA 02451
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments174294197
Cash and cash equivalents174294197
Other undisclosed current assets46971
Total current assets:642301198
Noncurrent Assets
Operating lease, right-of-use asset1
Property, plant and equipment5131
Restricted cash and investments21 
Other noncurrent assets  0
Total noncurrent assets:7151
TOTAL ASSETS:650316199
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities262314
Accounts payable1584
Accrued liabilities4149
Employee-related liabilities8  
Debt0  
Due to related parties000
Other undisclosed current liabilities15  
Total current liabilities:422314
Noncurrent Liabilities
Long-term debt and lease obligation0  
Operating lease, liability0
Liabilities, other than long-term debt211
Due to related parties111
Other liabilities100
Other undisclosed noncurrent liabilities 11 
Total noncurrent liabilities:2131
Total liabilities:443615
Stockholders' equity
Stockholders' equity attributable to parent, including:606280184
Common stock10 
Additional paid in capital1,026575380
Accumulated other comprehensive income0  
Accumulated deficit(421)(296)(196)
Other undisclosed stockholders' equity attributable to parent  0
Total stockholders' equity:606280184
TOTAL LIABILITIES AND EQUITY:650316199

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Gross profit:25  
Operating expenses(189)(104)(51)
Operating loss:(164)(104)(51)
Nonoperating income741
Other nonoperating income741
Interest and debt expense(0)(0)(0)
Loss before gain (loss) on sale of properties:(157)(100)(50)
Other undisclosed net income00 
Net loss:(157)(100)(50)
Other undisclosed net income attributable to parent0 0
Net loss available to common stockholders, diluted:(157)(100)(50)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
Net loss:(157)(100)(50)
Comprehensive loss:(157)(100)(50)
Other undisclosed comprehensive income, net of tax, attributable to parent0  
Comprehensive loss, net of tax, attributable to parent:(157)(100)(50)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: